Release no. 11/2011

Copenhagen and Oslo, 11th June, 2011, 2011-06-11 10:27 CEST (GLOBE NEWSWIRE) --



-- Rights and obligations under the R&D and Licensing Agreement
transferred from NTS Plus to new company IBC Generium

Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced
today that NauchTeckStroy Plus (NTS Plus) and Affitech A/S have amended their
Research & Development and Licensing Agreement signed in 2010. With this
amendment the rights and obligations under the R&D and Licensing Agreement will
be transferred from NTS Plus to the newly established Russian biotech company,
International Biotech Center Generium (IBC Generium) controlled by Aleksandr
Shuster and Victor Kharitonin, who through TransNova Investments Ltd. are
majority shareholders in Affitech A/S. Aleksandr Shuster is Chairman of
Affitech A/S.



About Affitech

Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules. Affitech co-develops its two lead antibody drug
candidates AT001/r84 and AT008/CCR4 with Russian partner IBC Generium. Further
information is available at www.affitech.com.


About International Biotech Center Generium (IBC Generium) and Nauch TechStroy
Plus (NTS Plus)

With reference to the Russian Pharma 2020 plan, which aims to increase national
production of innovative therapeutics NauchTechStroy Plus (NTS Plus) was
established as a construction company that should build a modern research park
in Pocrov/Russia. NTS Plus is controlled by the Russian biotech entrepreneur
Aleksandr Shuster and Russia's leading pharmaceutical company Pharmstandard
(LSE/MICEX/RTS: PHST), which is partly owned and chaired by Victor Kharitonin.
An important and central activity was to scout for an innovative therapeutic
product development portfolio for the new research park. In 2009/2010 Aleksandr
Shuster identified Affitech A/S as a collaboration partner and a collaboration
agreement was signed successfully in April 2010 between Affitech A/S and NTS
Plus as the only legal entity at the time. Having now finalized the
construction of the research park the shareholder group decided to separate the
construction activities from the research and development activities and
established a new company called International Biotechnology Center Generium
(IBC Generium). IBC Generium, which is controlled by Aleksandr Shuster and
Victor Kharitonin, will drive the science park's research and development
activities. Through TransNova Investments Ltd. owned by Aleksandr Shuster and
Victor Kharitonin, the two biotech and drug development entrepreneurs are
majority shareholders in Affitech A/S.

Disclaimer
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of the financial condition and operations of Affitech A/S. There are many
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements and
forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.


No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided
herein, and no claims shall be made by the recipient of this news release by
virtue of the information contained herein.



Contact:

Randi Krogsgaard, Director IR & Corporate Communications

Tel # +45 2320 1001, e-mail: [email protected]

110611 PR 11_2011_ Amendment UK.pdf